SCHEMBL3018532

SCHEMBL3018532

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(Br)c4)CC3)n2)c(OC)c1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 7/20 0.36
LMNA P02545 3/20 0.36
FKBP1A P62942 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
GPR6 P46095 2/20 0.36
HSD17B10 Q99714 3/20 0.36
USP2 O75604 1/20 0.36
RECQL P46063 1/20 0.36
HTR6 P50406 1/20 0.36
ALDH1A1 P00352 3/20 0.35
KDM4E B2RXH2 1/20 0.35
POLB P06746 1/20 0.35
HTT P42858 2/20 0.35
SMN1; SMN2 Q16637 3/20 0.35
RAB9A P51151 1/20 0.35
TP53 P04637 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
F2RL3 Q96RI0 4/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3016957 0.93 TP53 (0.37) MAPTLMNAFKBP1ATDP1GPR6
SCHEMBL3010966 0.91 MAPT (0.38) MAPTLMNAFKBP1ATDP1HSD17B10
SCHEMBL2999879 0.91 PSMD14 (0.37) MAPTFKBP1AGPR6HSD17B10USP2
SCHEMBL3017443 0.90 MAPT (0.41) MAPTLMNATDP1GPR6HSD17B10
SCHEMBL3004005 0.90 F2 (0.40) MAPTLMNATDP1GPR6HSD17B10
SCHEMBL3020230 0.88 KDM4E (0.42) MAPTLMNATDP1HSD17B10USP2
SCHEMBL3014895 0.88 MAPT (0.39) MAPTLMNAFKBP1AGPR6HSD17B10
SCHEMBL3022153 0.88 MAPT (0.43) MAPTLMNATDP1HSD17B10USP2
SCHEMBL3006435 0.88 MAPT (0.38) MAPTLMNATDP1HSD17B10ALDH1A1
SCHEMBL3001526 0.87 GPR6 (0.41) MAPTLMNAGPR6HSD17B10USP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA MAPT 18/4885LMNA 80/4885FKBP1A 1168/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.